Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AGAgenus Inc. logo

Agenus Inc. (AGEN)

NASDAQ Capital Market · Currency in USD
$6.33 ▼ -0.18 (-2.76%)
At close: Oct 23, 4:00 PM ET. Market closed.
$6.33 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:52 PM ET

Summary

Previous Close
$6.51
Open
$6.36
Day's Range
$6.15 – $6.50
52 Week Range
$2.71 – $10.31
Volume
509,035
Avg. Volume
3,272,757
Market Cap
$285.87M
Beta (5Y Monthly)
1.55
PE Ratio (TTM)
2.33
EPS (TTM)
$2.23
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$25.00

Profile: Agenus Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
81
CEO
Garo H. Armen

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $0.02 · Revenue est. $28.19M
DateEst.Actual
Aug 6, 2026$0.05-$0.01Miss
May 11, 2026$2.10$1.02Miss
Mar 16, 2026-$1.27$0.56Beat
Nov 10, 2025$2.63$1.94Miss
Aug 11, 2025-$0.78-$1.00Miss
May 12, 2025-$1.61-$1.03Beat

Analyst view

Consensus price target
$25.00 ▲ +294.9%
Range $25.00 – $25.00
Rating: Buy
Buy 83% · Hold 17% · Sell -0%

Get free alerts on AGEN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.